Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
11 juin 2024 04h00 HE
|
AKAMPION
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...
Elucida Oncology to Present at the Evercore ISI 2024 Emerging Biotech Conference
15 févr. 2024 11h45 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that Geno...
Thermosome Announces Further Dose Escalation in Phase I Trial with Lead Program THE001
06 févr. 2024 04h00 HE
|
AKAMPION
- First dose level rated as safe by independent Data Safety Monitoring Board- Second dose level to be administered according to plan- THE001 designed as targeted tumor treatment independent...
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
05 déc. 2023 04h00 HE
|
AKAMPION
- Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001 Munich, Germany – December 05, 2023 – Thermosome, a drug development company specializing...
Thermosome Establishes High-Profile Clinical Advisory Board
19 sept. 2023 04h00 HE
|
AKAMPION
Leveraging the transformative potential of TSL-based tumor targeting Supporting the progress of Thermosome's clinical candidate THE001 Munich, Germany – September 19, 2023 – Thermosome, a drug...
Elucida Oncology Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023
11 sept. 2023 10h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today an...
Elucida Oncology Appoints Ramzi Benamar as Chief Financial Officer
24 août 2023 11h00 HE
|
Elucida Oncology, Inc
MONMOUTH JUNCTION, N.J., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Elucida Oncology, a clinical-stage biotechnology company pioneering the next frontier in targeted cancer therapy, announced today that...
Cancer Monoclonal Antibodies Market Is A $108.47 Billion Opportunity; Successful Cancer Therapeutic Strategies
10 nov. 2022 07h02 HE
|
STRATEGIC MARKET RESEARCH LLP
New York, USA, Nov. 10, 2022 (GLOBE NEWSWIRE) -- The Worldwide Cancer Monoclonal Antibodies Market size in 2021 was USD 51.88 billion and will be worth USD 108.47 billion with an 8.54% CAGR. A...